ReviewMicrobial biotechnology2024
Bacterial synthesis of metal nanoparticles as antimicrobials.
Review in Microbial biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Remedial applications of biosynthesized metal oxide nanoparticles against pathogenic microorganisms.Discover nano · 2026Review
- Antioxidant and antibacterial properties of transition metals and metal oxides for medical uses: mechanisms, design strategies, and biomedical perspectives.Nanoscale advances · 2026Review
- Data-Driven Engineering of Antimicrobial Nanomaterials for Food Safety and Biomedical Systems.Nanomaterials (Basel, Switzerland) · 2026Review
- Biogenic nanoparticles: overview of challenges in production, characterization and use.Frontiers in chemistry · 2026Review
- Harnessing biogenic nanoparticles for combating antibiotic resistance: green synthesis, mechanistic insights, and biotechnological applications.Frontiers in bioengineering and biotechnology · 2026Review
- Biogenic nanoparticles from bacteria: a perspective on integrated applications in sustainable agriculture.Frontiers in microbiology · 2025Article
- Antibacterial, antifungal, and antibiofilm activities of biogenic zinc nanoparticles against pathogenic microorganisms.Frontiers in cellular and infection microbiology · 2025Article
- Microbes Saving Lives and Reducing Suffering.Microbial biotechnology · 2025Article
- Characterization and biological activity of selenium nanoparticles biosynthesized by Yarrowia lipolytica.Microbial biotechnology · 2024Article
- Bacterial synthesis of metal nanoparticles as antimicrobials.Microbial biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Nanoscience, a pivotal field spanning multiple industries, including healthcare, focuses on nanomaterials characterized by their dimensions. These materials are synthesized through conventional chemical and physical methods, often involving costly and energy-intensive processes. Alternatively, biogenic synthesis using bacteria, fungi, or plant extracts offers a potentially sustainable and non-toxic approach for producing metal-based nanoparticles (NP). This eco-friendly synthesis approach not only reduces environmental impact but also enhances features of NP production due to the unique biochemistry of the biological systems. Recent advancements have shown that along with chemically synthesized NPs, biogenic NPs possess significant antimicrobial properties. The inherent biochemistry of bacteria enables the efficient conversion of metal salts into NPs through reduction processes, which are further stabilized by biomolecular capping layers that improve biocompatibility and functional properties. This mini review explores the use of bacteria to produce NPs with antimicrobial activities. Microbial technologies to produce NP antimicrobials have considerable potential to help address the antimicrobial resistance crisis, thus addressing critical health issues aligned with the United Nations Sustainability Goal #3 of good health and well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.